Perspectives

Regulatory approval is no longer the finish line. In today's environment, biotech and pharma companies must design evidence generation strategies that satisfy regulators, payers, clinicians, and patients alike — from the outset. This article explores why demonstrating that a treatment works is only the starting point, and why demonstrating why it matters is what truly drives access and commercial success.